Open Orphan #ORPH – World’s first Covid-19 human challenge study to expand

Open Orphan (AIM: ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials, announces that hVIVO, a subsidiary of Open Orphan plc, is continuing to work with the UK Government to inoculate up to 20 further volunteers as part of the […]

Open Orphan #ORPH – Significant HRV & Influenza human challenge study contract win

Open Orphan (AIM: ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials, announces that hVIVO, a subsidiary of Open Orphan plc, has signed a significant contract with AIM ImmunoTech Inc (“AIM IT”) to test its antiviral candidate, Ampligen, using both […]

Open Orphan #ORPH – 2020 Annual Report and 2021 AGM Notice

Open Orphan plc (AIM: ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and a world leader in vaccine and antiviral testing using human challenge clinical trials, announces that the following documents have been sent to shareholders:  ·      Annual Report and Accounts for the year ended 31 December 2020 (“2020 Annual Report”) ·      […]

Andrew Hore – Quoted Micro 21 June 2021

AQUIS STOCK EXCHANGE CBD and hemp seed oil products supplier Voyager Life (VOY) has confirmed its flotation on Aquis on 30 June and the 295 Seedrs crowdfunding investors from earlier in 2021 will have the chance to participate in the associated fundraising. Seedrs Nominees Ltd currently owns 14.6%. A shop will be opened in St […]

Open Orphan #ORPH – Proposed Distribution in Specie & Notice of Results

Open Orphan plc (AIM: ORPH),  a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and a world leader in vaccine and antiviral testing using human challenge clinical trials , announces that, further to previous announcements, it proposes to make a distribution in specie of the entire issued share capital of its wholly-owned subsidiary Orph […]

Open Orphan #ORPH – Exercise of Warrants & TVR

Open Orphan plc (AIM: ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and a world leader in vaccine and antiviral testing using human challenge clinical trials , has received notice of exercise of warrants by investors, who participated in the Venn loan note financing in December 2018, over 404,806 ordinary shares of  0.1 pence […]

Open Orphan #ORPH – Court Approval to facilitate Distribution in Specie

Open Orphan (AIM: ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and a world leader in vaccine and antiviral testing using human challenge clinical trials, confirms that, following its announcement on 13 April 2021, it has received Court approval for the reduction in capital. The reduction of capital will become effective on […]

Open Orphan PLC #ORPH – Result of General Meeting

Result of General Meeting Open Orphan plc (AIM: ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and a world leader in vaccine and antiviral testing using human challenge clinical trials , announces that all resolutions proposed at the General Meeting held earlier today were duly passed. Further announcements regarding the proposed Distribution in Specie will […]